Belief BioMed Inc. (BBM), a Chinese biopharmaceutical company specializing in gene therapy, has announced a strategic partnership with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned subsidiary of Bayer AG. This collaboration aims to harness the potential of new gene therapies. The agreement will see the companies pool their expertise and resources in gene therapy to investigate potential treatments for diseases that could be addressed through liver-targeted gene therapy approaches.
Belief BioMed, known for its integrated approach to research, development, manufacturing, and clinical application of gene therapy products, is recognized for its recombinant adeno-associated virus (rAAV) vector delivery system, which has been well-received in the industry. AskBio, on the other hand, boasts an extensive gene therapy product pipeline that spans neuromuscular, central nervous system, cardiovascular, and metabolic disorders.- Flcube.com
